Justine0325 (Talk | contribs) |
|||
(29 intermediate revisions by 3 users not shown) | |||
Line 50: | Line 50: | ||
text-align: center; | text-align: center; | ||
margin: 0 auto; | margin: 0 auto; | ||
− | top: | + | top: 116%; |
left: 0%; | left: 0%; | ||
font-family: Corbel; | font-family: Corbel; | ||
Line 95: | Line 95: | ||
} | } | ||
.left { | .left { | ||
− | position: | + | padding: 10px; |
+ | height:200px; | ||
+ | border-color:#140731; | ||
+ | border-radius:8px; | ||
+ | border-width:2px; | ||
+ | border-style:solid; | ||
+ | position: absolute; | ||
left: 25px; | left: 25px; | ||
top: 230px; | top: 230px; | ||
Line 103: | Line 109: | ||
z-index:+1; | z-index:+1; | ||
} | } | ||
+ | |||
.left-tab { | .left-tab { | ||
background-color: rgba(250, 250, 250, 0.1); | background-color: rgba(250, 250, 250, 0.1); | ||
Line 126: | Line 133: | ||
border-radius: 4px; | border-radius: 4px; | ||
} | } | ||
+ | .fixed2 { | ||
+ | position: fixed; | ||
+ | top: 68px; | ||
+ | } | ||
+ | |||
.button { | .button { | ||
background-color: rgba(250, 250, 250, 0.1); | background-color: rgba(250, 250, 250, 0.1); | ||
Line 259: | Line 271: | ||
position: absolute; | position: absolute; | ||
width: 100%; | width: 100%; | ||
− | height: | + | height:290%; |
font-family: Corbel; | font-family: Corbel; | ||
z-index:+1; | z-index:+1; | ||
Line 267: | Line 279: | ||
position: absolute; | position: absolute; | ||
width: 20%; | width: 20%; | ||
− | height: | + | height: 39%; |
font-family: Corbel; | font-family: Corbel; | ||
} | } | ||
Line 307: | Line 319: | ||
} else { | } else { | ||
$('.header-subnav').removeClass('fixed1'); | $('.header-subnav').removeClass('fixed1'); | ||
+ | } | ||
+ | }); | ||
+ | var num = 132; //number of pixels before modifying styles | ||
+ | $(window).bind('scroll', function () { | ||
+ | if ($(window).scrollTop() > num) { | ||
+ | $('.left').addClass('fixed2'); | ||
+ | } else { | ||
+ | $('.left').removeClass('fixed2'); | ||
} | } | ||
}); | }); | ||
Line 366: | Line 386: | ||
</header> | </header> | ||
− | <div class="left | + | <div class="left"> |
− | <a href="#anchor1"><section class="left-tab" style=" | + | <a href="#anchor1"><section class="left-tab" style="top:240px;" id="myP" onmousedown="mouseDown()" onmouseup="mouseUp()"><b>TOP</b></section></a> |
− | <a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><section class="left-tab" style=" | + | <a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><section class="left-tab" style="top:275px;left:50px;">Overview</section></a> |
− | <a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><section class="left-tab" style=" | + | <a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><section class="left-tab" style="top:310px;left:50px;">Design</section></a> |
− | <a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><section class="left-tab" style=" | + | <a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><section class="left-tab" style="top:345px;left:50px;">Background</section></a> |
− | <a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><section class="left-tab" style=" | + | <a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><section class="left-tab" style="top:380px;left:50px;">Results</section></a> |
− | <a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><section class="left-tab" style=" | + | <a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><section class="left-tab" style="top:415px;left:50px;">Proof</section></a> |
− | <a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><section class="left-tab" style=" | + | <a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><section class="left-tab" style="top:450px;left:50px;">Notebook</section></a> |
</div> | </div> | ||
+ | |||
Line 386: | Line 407: | ||
<b><font size="5px">1. We established stable Leishmania transfectants and <br>proved the function of | <b><font size="5px">1. We established stable Leishmania transfectants and <br>proved the function of | ||
promotor with hygromycin drug selection gene</font></b> | promotor with hygromycin drug selection gene</font></b> | ||
− | <div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;margin-right:15%;"> | + | <div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;margin-right:15%;"><br> |
The promoter and the ribosomal binding site of Leishmania genome has not | The promoter and the ribosomal binding site of Leishmania genome has not | ||
been elucidated yet. We selected the 5'- untranslated region of a highly expressed | been elucidated yet. We selected the 5'- untranslated region of a highly expressed | ||
Line 408: | Line 429: | ||
<b><font size="6px">2. Successfully expressed Hemagglutinin of H1N1</font></b> | <b><font size="6px">2. Successfully expressed Hemagglutinin of H1N1</font></b> | ||
− | <div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;margin-right:15%;"> | + | <div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;margin-right:15%;"><br> |
Since we are performing immunology experiments, it is very important that the | Since we are performing immunology experiments, it is very important that the | ||
antigen is correctly expressed. We used BL21 competent cell to express the HA | antigen is correctly expressed. We used BL21 competent cell to express the HA | ||
Line 420: | Line 441: | ||
<b><font size="6px">3. The antibody production of Leijuvant in mice</font></b> | <b><font size="6px">3. The antibody production of Leijuvant in mice</font></b> | ||
− | <div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;margin-right:15%;"> | + | <div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;margin-right:15%;"><br> |
− | The IgG1 antibody titer increased drastically after the second boost on the | + | The IgG1 antibody titer increased drastically after the second boost on the 15<sup>th</sup> day. |
− | And the antibody titer reached to peak on the | + | And the antibody titer reached to peak on the 25<sup>th</sup> day <b>(Figure 4A.)</b>. Inactivated |
Leishmania can achieve over 60% of the antibody titer. As for OVA-expressing | Leishmania can achieve over 60% of the antibody titer. As for OVA-expressing | ||
− | inactivated Leishmania, the antibody titer can reach | + | inactivated Leishmania, the antibody titer can reach to 70% on the 25<sup>th</sup> day. The |
− | IgG2a antibody titer of inactivated Leishmania increased extremely on the | + | IgG2a antibody titer of inactivated Leishmania increased extremely on the 20<sup>th</sup> day |
− | and is significantly higher compare to Alum on the | + | and is significantly higher compare to Alum on the 25<sup>th</sup> day<b>(Figure 4B.)</b>. <b>Leijuvant</b> is a |
− | potential bi-pathway adjuvant that can stimulate both Th1 and Th2 immune | + | potential <b>bi-pathway</b> adjuvant that can stimulate both Th1 and Th2 immune |
responses.<br><br> | responses.<br><br> | ||
− | <img src="https://static.igem.org/mediawiki/2016/ | + | <img src="https://static.igem.org/mediawiki/2016/5/5a/CGU_Taiwan_result_final.png" width=850px height=500px margin-right=15%></img><br><br> |
<br> | <br> | ||
</div> | </div> | ||
Line 436: | Line 457: | ||
− | <div class="end2" style="margin-top: | + | <div class="end2" style="margin-top:220%;"> |
<br> | <br> | ||
<ul class="list3" class="margin-left:1%;margin-top:2%;"> | <ul class="list3" class="margin-left:1%;margin-top:2%;"> | ||
Line 444: | Line 465: | ||
<div class="sitemap" style="margin-left:5%;"> | <div class="sitemap" style="margin-left:5%;"> | ||
<br> | <br> | ||
− | <b style="color:white;font-size: | + | <b style="color:white;font-size:28px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</b><br> |
<br><br> | <br><br> | ||
<img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:40%;height:70%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg"> | <img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:40%;height:70%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg"> | ||
Line 450: | Line 471: | ||
<br> | <br> | ||
− | <div class="sitemap" style="margin-left: | + | <div class="sitemap" style="margin-left:22%;margin-top:-1%;"> |
<ul class="list1" class="margin-left:5%;"> | <ul class="list1" class="margin-left:5%;"> | ||
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li></a> |
</ul> | </ul> | ||
</div> | </div> | ||
Line 462: | Line 483: | ||
<div class="sitemap" style="margin-left:40%;margin-top:-2%;"> | <div class="sitemap" style="margin-left:40%;margin-top:-2%;"> | ||
<ul class="list1" class="margin-left:5%;"> | <ul class="list1" class="margin-left:5%;"> | ||
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li></a> |
− | <br> | + | <br><br> |
<ul class="list2" class="margin-left:6%;margin-top:50%;"> | <ul class="list2" class="margin-left:6%;margin-top:50%;"> | ||
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li></a> |
<br><br> | <br><br> | ||
</ul> | </ul> | ||
Line 477: | Line 498: | ||
<div class="sitemap" style="margin-left:55%;margin-top:-3.5%;"> | <div class="sitemap" style="margin-left:55%;margin-top:-3.5%;"> | ||
<ul class="list1" class="margin-left:5%;"> | <ul class="list1" class="margin-left:5%;"> | ||
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li></a> |
− | <br> | + | <br><br> |
<ul class="list2" class="margin-left:6%;margin-top:50%;"> | <ul class="list2" class="margin-left:6%;margin-top:50%;"> | ||
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li></a> |
</ul> | </ul> | ||
</ul> | </ul> | ||
Line 490: | Line 511: | ||
<div class="sitemap" style="margin-left:75%;margin-top:-3.5%;"> | <div class="sitemap" style="margin-left:75%;margin-top:-3.5%;"> | ||
<ul class="list1" class="margin-left:5%;"> | <ul class="list1" class="margin-left:5%;"> | ||
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li></a> |
− | <br> | + | <br><br> |
<ul class="list2" class="margin-left:6%;"> | <ul class="list2" class="margin-left:6%;"> | ||
− | <li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li> | + | <li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li></a> |
</ul> | </ul> | ||
</ul> | </ul> | ||
<ul class="list1" class="margin-left:1%;margin-top:-10%;"> | <ul class="list1" class="margin-left:1%;margin-top:-10%;"> | ||
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li></a> |
− | <br> | + | <br><br> |
<ul class="list2" class="margin-left:6%;margin-top:-5%;"> | <ul class="list2" class="margin-left:6%;margin-top:-5%;"> | ||
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li></a> |
− | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li> | + | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li></a> |
+ | <li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team#anchor2"><b style="color:white;font-size:17px;margin-left:10%;">Sponsors</li></a> | ||
</ul> | </ul> | ||
</ul> | </ul> | ||
</div> | </div> | ||
</div> | </div> | ||
+ | |||
+ | |||
</body> | </body> | ||
</html> | </html> |
Latest revision as of 06:01, 2 December 2016
![](https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg)
![](https://static.igem.org/mediawiki/2016/8/8a/CGU_Taiwan--logo9.jpg)
Proof of Concept
1. We established stable Leishmania transfectants and
proved the function of promotor with hygromycin drug selection gene
The promoter and the ribosomal binding site of Leishmania genome has not been elucidated yet. We selected the 5'- untranslated region of a highly expressed gene, P36, to be the promoter, RBS binding site and other extra function needed for Leishmania protein expression. We also added a hygromycin resist gene to serve as a dual functional biobrick of regulatory and selection marker. We provide the user with the regulation of protein expression and also the drug selection system that is most commonly and effectively used in Leishmania experiments. The pSB1C3-5'HYG-OVA-3'UTR was transfected into Leishmania 12-DT strain, and the transfectants were selected by hygromycin. We obtained the hygromycin-resistant Leishmania transfectants (Figure 1. B, C). In the negative control group (Figure 1. A), we could see that almost all cells were dead and the shape of Leishmania was not normal. It showed that Leishmania transfectants were resistant to high concentration of hygromycin. The function of 5’HYG was assayed more precisely in figure 2.
![](https://static.igem.org/mediawiki/2016/3/37/Proof1.jpeg)
2. Successfully expressed Hemagglutinin of H1N1
Since we are performing immunology experiments, it is very important that the antigen is correctly expressed. We used BL21 competent cell to express the HA sequence and detect the protein by Western blot analysis.
The pSB1C3-J04500-HA can is checked by Western blot analysis. We successfully recognize the HA protein from Western blot analysis (approximately 62.3kd) when induced by IPTG (Figure 3.).
![](https://static.igem.org/mediawiki/2016/4/4e/Proof2.jpeg)
3. The antibody production of Leijuvant in mice
The IgG1 antibody titer increased drastically after the second boost on the 15th day. And the antibody titer reached to peak on the 25th day (Figure 4A.). Inactivated Leishmania can achieve over 60% of the antibody titer. As for OVA-expressing inactivated Leishmania, the antibody titer can reach to 70% on the 25th day. The IgG2a antibody titer of inactivated Leishmania increased extremely on the 20th day and is significantly higher compare to Alum on the 25th day(Figure 4B.). Leijuvant is a potential bi-pathway adjuvant that can stimulate both Th1 and Th2 immune responses.
![](https://static.igem.org/mediawiki/2016/5/5a/CGU_Taiwan_result_final.png)